ALK and non-small cell lung carcinoma: In the PROFILE 1014 study, 343 patients with ALK-rearranged nonsquamous NSCLC were randomly assigned to receive crizotinb (172 patients) or cisplatin plus pemetrexed (171 patients), the most effective chemotherapy regimen in patients with nonsquamous NSCLC.